Sartorius AG

SRT

Company Profile

  • Business description

    Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.

  • Contact

    Otto-Brenner-Strasse 20
    GottingenNI37079
    DEU

    T: +49 5513080

    E: [email protected]

    https://www.sartorius.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2025

    Employees

    13,685

Stocks News & Analysis

stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.
stocks

Is there a long-term buying opportunity in luxury stocks?

Our analysts think the recent wobble in revenue growth is cyclical, not structural.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,102.1011.700.13%
CAC 407,830.1123.48-0.30%
DAX 4023,527.05112.36-0.48%
Dow JONES (US)46,381.5466.270.14%
FTSE 1009,226.6810.010.11%
HKSE26,344.14200.96-0.76%
NASDAQ22,788.98157.500.70%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,126.6114.93-0.11%
S&P 5006,693.7529.390.44%
S&P/ASX 2008,810.9011.400.13%
SSE Composite Index3,828.588.490.22%

Market Movers